DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Receives $12.33 Consensus PT from Analysts

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) has received an average rating of “Moderate Buy” from the seven research firms that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $12.3333.

A number of research firms have recently commented on DMAC. Cantor Fitzgerald started coverage on DiaMedica Therapeutics in a research report on Friday, November 14th. They set an “overweight” rating on the stock. Wall Street Zen cut DiaMedica Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 15th. TD Cowen began coverage on DiaMedica Therapeutics in a research note on Thursday, October 30th. They set a “buy” rating for the company. Cowen started coverage on shares of DiaMedica Therapeutics in a research note on Thursday, October 30th. They issued a “buy” rating on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of DiaMedica Therapeutics in a report on Wednesday, October 8th.

Insider Activity at DiaMedica Therapeutics

In related news, major shareholder Jan Stahlberg purchased 73,099 shares of DiaMedica Therapeutics stock in a transaction that occurred on Tuesday, November 25th. The stock was purchased at an average price of $8.57 per share, for a total transaction of $626,458.43. Following the transaction, the insider directly owned 8,825,742 shares in the company, valued at approximately $75,636,608.94. This trade represents a 0.84% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Insiders have bought a total of 1,061,277 shares of company stock worth $7,632,627 over the last three months. 7.30% of the stock is owned by insiders.

Institutional Investors Weigh In On DiaMedica Therapeutics

Several large investors have recently bought and sold shares of the company. Russell Investments Group Ltd. purchased a new position in shares of DiaMedica Therapeutics in the third quarter valued at approximately $27,000. Police & Firemen s Retirement System of New Jersey acquired a new position in DiaMedica Therapeutics in the 2nd quarter valued at $29,000. Bank of America Corp DE lifted its holdings in DiaMedica Therapeutics by 3,710.3% in the 2nd quarter. Bank of America Corp DE now owns 8,497 shares of the company’s stock valued at $33,000 after purchasing an additional 8,274 shares in the last quarter. JPMorgan Chase & Co. purchased a new position in DiaMedica Therapeutics in the 2nd quarter valued at $49,000. Finally, Invesco Ltd. acquired a new stake in DiaMedica Therapeutics during the 2nd quarter worth $54,000. 10.12% of the stock is currently owned by hedge funds and other institutional investors.

DiaMedica Therapeutics Price Performance

DMAC opened at $8.35 on Friday. The firm has a fifty day moving average price of $7.56 and a 200 day moving average price of $6.09. DiaMedica Therapeutics has a 1 year low of $3.19 and a 1 year high of $10.42. The stock has a market cap of $434.87 million, a P/E ratio of -11.76 and a beta of 1.31.

DiaMedica Therapeutics (NASDAQ:DMAC) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.02). Equities analysts expect that DiaMedica Therapeutics will post -0.59 EPS for the current year.

About DiaMedica Therapeutics

DiaMedica Therapeutics, Inc (NASDAQ: DMAC) is a clinical‐stage biopharmaceutical company focused on developing novel therapies for acute and chronic central nervous system conditions. The company’s lead product candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to promote neuroprotection and tissue repair through modulation of the kallikrein‐kinin system. DiaMedica’s research and development efforts are centered on translating the regenerative potential of DM199 into effective treatments for disorders with high unmet medical need.

DM199 is being evaluated in acute ischemic stroke, where preclinical studies have demonstrated potential benefits in blood flow restoration, inflammation reduction and neuronal survival.